{"filing":{"accession_number":"0001104659-26-070494","cik":"0001557746","ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"acrs-20260604x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926070494/acrs-20260604x8k.htm"},"events":[{"id":6737,"run_id":5900,"accession_number":"0001104659-26-070494","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from Aclaris Therapeutics' 2026 annual meeting held on June 4, 2026. The filing reports voting outcomes for three proposals: election of two directors (Anand Mehra, M.D. and Maxine Gowen, Ph.D.), advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. The detailed vote tallies (For, Against, Withheld, Abstained, and Broker Non-Votes) are characteristic of Item 5.07 shareholder vote results disclosures.","company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4247,"accession_number":"0001104659-26-070494","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Aclaris Therapeutics' 2026 annual meeting held on June 4, 2026. The filing reports voting outcomes for three proposals: election of two directors (Anand Mehra, M.D. and Maxine Gowen, Ph.D.), advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. The detailed vote tallies (For, Against, Withheld, Abstained, and Broker Non-Votes) are characteristic of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:51:55.148894+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4247,"accession_number":"0001104659-26-070494","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Aclaris Therapeutics' 2026 annual meeting held on June 4, 2026. The filing reports voting outcomes for three proposals: election of two directors (Anand Mehra, M.D. and Maxine Gowen, Ph.D.), advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. The detailed vote tallies (For, Against, Withheld, Abstained, and Broker Non-Votes) are characteristic of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:51:55.148894+00:00","company_name":"Aclaris Therapeutics, Inc.","ticker":"ACRS","filing_date":"2026-06-04"}]}